NEW Nanotechnology from Northeastern University to Make Non-Soluble Drugs Soluble – in partnership with One Million Solutions in Health

The Technology Evaluation Consortium™ (TEC), managed by One Million Solutions in Health™, recently completed a successful Phase I TEC Validation Project™. In this Phase I project, it was shown that the patented nanoparticle technology process developed by researchers at Northeastern University could incorporate compounds, such as poorly water-soluble drugs, into an assembly of fully functional nanoparticle structures. Based on this success, the TEC and the Center for High-rate Nanomanufacturing (CHN) have announced their intention to begin a Phase II TEC Validation Project™.

Dr. Ahmed Busnaina, the Director of the CHN, and a Distinguished Professor and holder of the WL Smith Chair at Northeastern University in Boston, is the lead investigator responsible for developing the nanoparticle technology. This new manufacturing process produces nanoparticle structures with a unique ability to pass through normal tissue boundaries. The research team has found that nano-sized particles can be fabricated into distinct shapes, such as nanopillars, with controlled size and shape that could potentially have high tissue permeability. This process could have far-reaching impacts, including important applications within the pharmaceutical industry.

The goals of a Phase II Validation Project will be three-fold. Firstly, researchers wish to increase the number of drug-loaded nanorods for in vitro characterization. Success in this area will demonstrate the feasibility of fabricating drug-loaded nanorods with sufficient drug dosage to perform in vitro characterization for the next two goals. The second goal is to evaluate the in vitro permeability and cytotoxicity of drug-loaded micellar nanorods in cell lines. The final goal is to evaluate in vivo permeability and cytotoxicity of drug-loaded micellar nanorods in animal studies.

“We are excited to be advancing to the next step with Northeastern University,” explained Dawn Van Dam, President and CEO of One Million Solutions in Health. “The team at CHN have developed highly relevant and unique nanoparticle technology that will be extraordinarily helpful for the pharmaceutical industry, once the technology is validated by the Technology Evaluation Consortium.”

The consortium will bring together a number of industry leaders from pharmaceutical companies to evaluate and further qualify the CHN’s patented nanoparticle technology process. Consortium members and pharma experts affiliated with the university will share ideas and solutions with the hopes of creating a likely path of adoption for Northeastern University’s nanoparticle technology.

We are working with leading companies like AbbVie, Allergan, Amgen, Janssen (Johnson & Johnson) and Novartis – and expect to have the results from this nanoparticle technology evaluation to be applicable to dozens of pharmaceutical and other medicinal companies that struggle with formulating non-soluble compounds (intravenous) so that the drugs can be swallowed, instead.

In the end, this will allow more patients to be able to access important medications, thereby enhancing the success of medical care in many diseases.

(LINK TO PRESS RELEASE ABOUT THE LAUNCH OF PHASE I PROJECT:http://www.prweb.com/releases/2016/02/prweb13192064.htm
LINK TO PRESS RELEASE ANNOUNCING THE COMPLETION OF PHASE I PROJECT:
http://www.prweb.com/releases/2016/02/prweb13192206.htm)